Clopidogrel Pathway

Overview

Journal Pharmacogenet Genomics

Specialties Genetics
Pharmacology

Date 2010 May 5

PMID 20440227

Citations 92

Authors

Katrin Sangkuhl

Teri E Klein

Russ B Altman

Affiliations

Soon will be listed here.

Citing Articles

In Vitro Analysis of AKR1D1 Interactions with Clopidogrel: Effects on Enzyme Activity and Gene Expression.

Shutevska K, Kadifkova P, Zhivikj Z, Kapedanovska N Balkan J Med Genet. 2025; 27(2):69-75.

PMID: 40070864 PMC: 11892939. DOI: 10.2478/bjmg-2024-0012.

Association of c.681G>A (rs4244285) Loss-of-function Allele with Cardiovascular Disease Risk in the Kosovo Population.

Elshani N, Ukella K, Staninova S, Naumovska Z, Kurshumliu M, Gorani D Balkan J Med Genet. 2025; 27(2):77-85.

PMID: 40070858 PMC: 11892937. DOI: 10.2478/bjmg-2024-0015.

Phase 1 study of novel anti-platelet agent to overcome pharmacogenomic limitations of clopidogrel.

Pareek A, Chandurkar N, Raut V, Naidu K Open Heart. 2025; 12(1).

PMID: 39933830 PMC: 11815446. DOI: 10.1136/openhrt-2024-003088.

TICA-CLOP STUDY: Ticagrelor Versus Clopidogrel in Acute Moderate and Moderate-to-Severe Ischemic Stroke, a Randomized Controlled Multi-Center Trial.

Ahmed S, Nahas N, Elsayed Khalil M, ElBassiouny A, Almoataz M, Omar T CNS Drugs. 2024; 39(1):81-93.

PMID: 39520630 PMC: 11695443. DOI: 10.1007/s40263-024-01127-7.

Optimized Methodology to Produce Platelet-Rich Plasma and Perform Platelet Aggregation in Patients With Coronary Artery Disease.

Kashyap A, Saikrishna B, Duggal B Cureus. 2024; 16(9):e69032.

PMID: 39391413 PMC: 11464479. DOI: 10.7759/cureus.69032.

References

Clarke T, Waskell L . The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos. 2002; 31(1):53-9. DOI: 10.1124/dmd.31.1.53. View

Saw J, Brennan D, Steinhubl S, Bhatt D, Mak K, Fox K . Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol. 2007; 50(4):291-5. DOI: 10.1016/j.jacc.2007.01.097. View

Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N . Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2008; 360(4):363-75. DOI: 10.1056/NEJMoa0808227. View

Cuisset T, Frere C, Quilici J, Poyet R, Gaborit B, Bali L . Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol. 2009; 54(13):1149-53. DOI: 10.1016/j.jacc.2009.05.050. View

Lins R, BROEKHUYSEN J, Necciari J, Deroubaix X . Pharmacokinetic profile of 14C-labeled clopidogrel. Semin Thromb Hemost. 1999; 25 Suppl 2:29-33. View

Hulot J, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C . Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006; 108(7):2244-7. DOI: 10.1182/blood-2006-04-013052. View

Collet J, Hulot J, Pena A, Villard E, Esteve J, Silvain J . Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2008; 373(9660):309-17. DOI: 10.1016/S0140-6736(08)61845-0. View

Caplain H, Donat F, Gaud C, Necciari J . Pharmacokinetics of clopidogrel. Semin Thromb Hemost. 1999; 25 Suppl 2:25-8. View

Farid N, Payne C, Small D, Winters K, Ernest 2nd C, Brandt J . Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007; 81(5):735-41. DOI: 10.1038/sj.clpt.6100139. View

10.

Savi P, Herbert J, Pflieger A, Dol F, Delebassee D, Combalbert J . Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol. 1992; 44(3):527-32. DOI: 10.1016/0006-2952(92)90445-o. View

11.

Rude M, Chey W . Proton-pump inhibitors, clopidogrel, and cardiovascular adverse events: fact, fiction, or something in between?. Gastroenterology. 2009; 137(3):1168-71. DOI: 10.1053/j.gastro.2009.07.011. View

12.

Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid N, Okazaki O . Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2009; 38(1):92-9. DOI: 10.1124/dmd.109.029132. View

13.

Ho P, Maddox T, Wang L, Fihn S, Jesse R, Peterson E . Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009; 301(9):937-44. DOI: 10.1001/jama.2009.261. View

14.

Savi P, Pereillo J, Uzabiaga M, Combalbert J, Picard C, Maffrand J . Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000; 84(5):891-6. View

15.

Lotfi A, Schweiger M, Giugliano G, Murphy S, Cannon C . High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients--a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI.... Am Heart J. 2008; 155(5):954-8. DOI: 10.1016/j.ahj.2007.12.009. View

16.

Siller-Matula J, Lang I, Christ G, Jilma B . Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol. 2008; 52(19):1557-63. DOI: 10.1016/j.jacc.2008.07.055. View

17.

Fontana P, Senouf D, Mach F . Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness. Thromb Res. 2007; 121(4):463-8. DOI: 10.1016/j.thromres.2007.06.012. View

18.

Mega J, Close S, Wiviott S, Shen L, Hockett R, Brandt J . Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2008; 360(4):354-62. DOI: 10.1056/NEJMoa0809171. View

19.

Geisler T, Schaeffeler E, Dippon J, Winter S, Buse V, Bischofs C . CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics. 2008; 9(9):1251-9. DOI: 10.2217/14622416.9.9.1251. View

20.

Giusti B, Gori A, Marcucci R, Saracini C, Sestini I, Paniccia R . Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics. 2007; 17(12):1057-64. DOI: 10.1097/FPC.0b013e3282f1b2be. View